AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $367.35 billion. The enterprise value is $431.01 billion.
| Market Cap | 367.35B |
| Enterprise Value | 431.01B |
Important Dates
The next estimated earnings date is Friday, April 24, 2026, before market open.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | Apr 15, 2026 |
Share Statistics
AbbVie has 1.77 billion shares outstanding.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.11% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 75.29% |
| Float | 1.77B |
Valuation Ratios
The trailing PE ratio is 86.95 and the forward PE ratio is 14.12. AbbVie's PEG ratio is 0.79.
| PE Ratio | 86.95 |
| Forward PE | 14.12 |
| PS Ratio | 6.01 |
| Forward PS | 5.42 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 20.65 |
| P/OCF Ratio | 19.33 |
| PEG Ratio | 0.79 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.73, with an EV/FCF ratio of 24.19.
| EV / Earnings | 102.96 |
| EV / Sales | 7.05 |
| EV / EBITDA | 14.73 |
| EV / EBIT | 20.41 |
| EV / FCF | 24.19 |
Financial Position
The company has a current ratio of 0.67
| Current Ratio | 0.67 |
| Quick Ratio | 0.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.31 |
| Debt / FCF | 3.84 |
| Interest Coverage | 7.30 |
Financial Efficiency
Return on equity (ROE) is 6,225.00% and return on invested capital (ROIC) is 22.49%.
| Return on Equity (ROE) | 6,225.00% |
| Return on Assets (ROA) | 9.81% |
| Return on Invested Capital (ROIC) | 22.49% |
| Return on Capital Employed (ROCE) | 23.29% |
| Weighted Average Cost of Capital (WACC) | 5.56% |
| Revenue Per Employee | $1.07M |
| Profits Per Employee | $73,439 |
| Employee Count | 57,000 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 3.80 |
Taxes
In the past 12 months, AbbVie has paid $2.36 billion in taxes.
| Income Tax | 2.36B |
| Effective Tax Rate | 35.83% |
Stock Price Statistics
The stock price has decreased by -0.51% in the last 52 weeks. The beta is 0.33, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -0.51% |
| 50-Day Moving Average | 222.20 |
| 200-Day Moving Average | 215.52 |
| Relative Strength Index (RSI) | 33.94 |
| Average Volume (20 Days) | 7,331,954 |
Short Selling Information
The latest short interest is 21.75 million, so 1.23% of the outstanding shares have been sold short.
| Short Interest | 21.75M |
| Short Previous Month | 19.68M |
| Short % of Shares Out | 1.23% |
| Short % of Float | 1.23% |
| Short Ratio (days to cover) | 3.07 |
Income Statement
In the last 12 months, AbbVie had revenue of $61.16 billion and earned $4.19 billion in profits. Earnings per share was $2.36.
| Revenue | 61.16B |
| Gross Profit | 43.80B |
| Operating Income | 21.12B |
| Pretax Income | 6.60B |
| Net Income | 4.19B |
| EBITDA | 29.25B |
| EBIT | 21.12B |
| Earnings Per Share (EPS) | $2.36 |
Balance Sheet
The company has $5.26 billion in cash and $68.40 billion in debt, with a net cash position of -$63.14 billion or -$35.71 per share.
| Cash & Cash Equivalents | 5.26B |
| Total Debt | 68.40B |
| Net Cash | -63.14B |
| Net Cash Per Share | -$35.71 |
| Equity (Book Value) | -3.23B |
| Book Value Per Share | -1.85 |
| Working Capital | -14.23B |
Cash Flow
In the last 12 months, operating cash flow was $19.03 billion and capital expenditures -$1.21 billion, giving a free cash flow of $17.82 billion.
| Operating Cash Flow | 19.03B |
| Capital Expenditures | -1.21B |
| Depreciation & Amortization | 8.14B |
| Net Borrowing | -304.00M |
| Free Cash Flow | 17.82B |
| FCF Per Share | $10.08 |
Margins
Gross margin is 71.62%, with operating and profit margins of 34.52% and 6.91%.
| Gross Margin | 71.62% |
| Operating Margin | 34.52% |
| Pretax Margin | 10.79% |
| Profit Margin | 6.91% |
| EBITDA Margin | 47.83% |
| EBIT Margin | 34.52% |
| FCF Margin | 29.13% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 3.33%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 3.33% |
| Dividend Growth (YoY) | 5.64% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 285.59% |
| Buyback Yield | n/a |
| Shareholder Yield | 3.33% |
| Earnings Yield | 1.14% |
| FCF Yield | 4.84% |
Analyst Forecast
The average price target for AbbVie is $247.06, which is 18.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $247.06 |
| Price Target Difference | 18.92% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 6.79% |
| EPS Growth Forecast (5Y) | 53.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.26 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.26 |
| Piotroski F-Score | 8 |